Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Kits > PD-1 > EP-130

PD-1 : PD-L1 [Biotinylated] Inhibitor Screening ELISA Kit

For research use only.
EP130-C01High-bind Plate1plate
EP130-C02Human PD-110μg
EP130-C03Biotinylated Human PD-L120μg
EP130-C04Anti-PD-1 Neutralizing Antibody20μg
EP130-C06Coating Buffer12mL
EP130-C0710xWashing Buffer 50mL
EP130-C08Blocking Buffer50mL
EP130-C09Substrate Solution24mL
EP130-C10Stop Solution7mL
  • Background
    Immune checkpoint pathway is a focal point of today’s cancer research. PD-1 is one of the best characterized checkpoint proteins. The binding between PD-1 and its ligand PD-L1 suppresses T-cell activation and allows cancer cells to escape from body’s immune surveillance. Therefore, the pharmaceutical inhibition of PD-1 or its ligand has been considered a promising strategy by many oncologists.
  • Application

    The inhibitor screening ELISA kit is designed to facilitate the identification and characterization of new PD-1 pathway inhibitors.

    It is for research use only.

  • Reconstitution
    Please see Certificate of Analysis for details of reconstitution instruction and specific concentration.
  • Storage
    The unopened kit is stable for 12 months from the date of manufacture if stored at 2°C to 8°C.
  • Assay Principles
    This inhibitor screening ELISA kit is designed to facilitate the identification and characterization of new PD-1 pathway inhibitors. The assay takes advantage of our in house-developed binding of biotinylated human PD-L1 to immobilized human PD-1 in a functional ELISA assay, and employs a simple colorimetric ELISA platform. Briefly, we provide you with a human Biotinylated PD-L1 protein, a human PD-1 protein, an anti-PD-1 neutralizing antibody (as method verified Std.), and Streptavidin-HRP reagent.

    Your experiment will include 4 simple steps:

    a) Coat the plate with human PD-1.

    b) Add your molecule of interest to the tests.

    c) Add human PD-L1-Biotin to bind the coated human PD-1.

    d) Add Streptavidin-HRP followed by TMB or other colorimetric HRP substrate.

    Finally, the half maximal inhibitory concentration (IC50) of your compound to PD-1: PD-L1 binding will be determined by comparing OD readings among different experimental groups.

Typical Data Please refer to DS document for The assay protocol.

Serial dilutions of Anti-PD-1 Neutralizing antibody (Catalog # EP130-C04) (1:1 serial dilution, from 5μg/mL to 0.02μg/mL) was added into PD-1: Biotinylated PD-L1 binding reactions. The assay was performed according to the protocol described below. Background was subtracted from data points prior to log transformation and curve fitting (QC tested).

Comments (0)

ETD of in-stock products: 2 business days

Price(USD) : $600.00

Promotion & Exhibitions

Drug Development Status

  • Number of Launched Drugs:15 Details
  • Number of Drugs in Clinical Trials:122 Details
  • Latest Research Phase:Approved

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message